Shionogi to Acquire IntraBio for $2 Billion

Japanese drugmaker Shionogi will buy U.S.-based IntraBio for $2 billion to expand its rare disease drug business.

Why it matters. Shionogi gains access to IntraBio's talent and sales channels, potentially accelerating its growth in the rare disease market.